KR20240046787A - 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제 - Google Patents

지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제 Download PDF

Info

Publication number
KR20240046787A
KR20240046787A KR1020247009783A KR20247009783A KR20240046787A KR 20240046787 A KR20240046787 A KR 20240046787A KR 1020247009783 A KR1020247009783 A KR 1020247009783A KR 20247009783 A KR20247009783 A KR 20247009783A KR 20240046787 A KR20240046787 A KR 20240046787A
Authority
KR
South Korea
Prior art keywords
mrna
temperature
freeze
drying
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247009783A
Other languages
English (en)
Korean (ko)
Inventor
스와르넨두 카비라즈
산자이 싱
수닐 라우트
파반 카르딜
아자이 싱
Original Assignee
젠노바 바이오파마슈티컬스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠노바 바이오파마슈티컬스 리미티드 filed Critical 젠노바 바이오파마슈티컬스 리미티드
Publication of KR20240046787A publication Critical patent/KR20240046787A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247009783A 2021-08-25 2022-08-24 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제 Pending KR20240046787A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121038492A IN202121038492A (https=) 2021-08-25 2021-08-25
IN202121038492 2021-08-25
PCT/IN2022/050753 WO2023026301A1 (en) 2021-08-25 2022-08-24 LYOPHILISED FORMULATIONS OF mRNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES

Publications (1)

Publication Number Publication Date
KR20240046787A true KR20240046787A (ko) 2024-04-09

Family

ID=85321644

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247009783A Pending KR20240046787A (ko) 2021-08-25 2022-08-24 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제

Country Status (11)

Country Link
US (1) US20240350413A1 (https=)
EP (1) EP4392023A4 (https=)
JP (1) JP7821271B2 (https=)
KR (1) KR20240046787A (https=)
AU (1) AU2022335015B2 (https=)
CA (1) CA3229958A1 (https=)
CL (1) CL2024000566A1 (https=)
CO (1) CO2024002142A2 (https=)
IN (1) IN202121038492A (https=)
WO (1) WO2023026301A1 (https=)
ZA (1) ZA202402153B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
WO2024261766A1 (en) * 2023-06-23 2024-12-26 Gennova Biopharmaceuticals Ltd. Lyophilised vaccine formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4026568A1 (en) * 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
US20240350410A1 (en) * 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof

Also Published As

Publication number Publication date
EP4392023A1 (en) 2024-07-03
ZA202402153B (en) 2024-10-30
IN202121038492A (https=) 2023-03-03
WO2023026301A1 (en) 2023-03-02
US20240350413A1 (en) 2024-10-24
JP2024532292A (ja) 2024-09-05
EP4392023A4 (en) 2025-07-09
CO2024002142A2 (es) 2024-04-18
AU2022335015A1 (en) 2024-03-14
CL2024000566A1 (es) 2024-09-23
CA3229958A1 (en) 2023-03-02
AU2022335015B2 (en) 2025-04-10
JP7821271B2 (ja) 2026-02-26

Similar Documents

Publication Publication Date Title
KR20240046787A (ko) 지질 나노-에멀젼 입자에 흡착된 mRNA의 동결건조 제제
KR101695800B1 (ko) 항원보강제 함유 백신 조성물의 안정화 방법
RU2465007C2 (ru) Препарат вакцины на основе конъюгата никотин-носитель
JP2002506048A (ja) ポリヌクレオチド組成物、その製造方法および使用
RU2735082C2 (ru) Способ получения лиофилизированных пеллет, содержащих фактор viii
US20260007604A1 (en) USE OF A SPRAY FREEZE-DRYING PROCESS FOR THE LYOPHILIZATION OF A mRNA-ENCAPSULATING LIPID NANOPARTICLES FORMULATION
WO2009056651A1 (en) Angiotensin-carrier formulation
CN116549626A (zh) 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
Coleman et al. Stabilization of an infectious enveloped virus by spray-drying and lyophilization
EP2437787B1 (en) A virus-like particle vector for delivery of pharmaceutical agents, a process for the manufacture thereof, its uses and a pharmaceutical composition.
CN114224851A (zh) 一种人白细胞介素10-Fc融合蛋白的冻干粉制剂及制备方法
EP1555033A2 (en) Polynucleotide composition, method of preparation, and use thereof
KR102458982B1 (ko) 아주반트
Trenkenschuh Freeze-drying of nanoparticles: impact of particle properties on formulation and process development
EA050946B1 (ru) ЛИОФИЛИЗИРОВАННЫЕ ПРЕПАРАТЫ мРНК, АДСОРБИРОВАННОЙ НА ЛИПИДНЫХ ЧАСТИЦАХ НАНОЭМУЛЬСИИ
Mody et al. Freeze-drying of protein-loaded nanoparticles for vaccine delivery
TW202346584A (zh) 含核酸組合物之連續旋轉冷凍乾燥
Zhen et al. Drying technologies for messenger RNA and other nucleic acid-lipid nanoparticles: Advances in freeze-drying and beyond
CN115350281B (zh) 一种病毒样颗粒疫苗冻干保护剂及其制备方法
KR100729954B1 (ko) Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
JP2018104388A (ja) 凍結乾燥製剤の製造方法
CN117379393A (zh) 一种核酸药物黏膜给药制剂及其制备方法和应用
CN121154559A (zh) 一种载核酸脂质纳米颗粒的冻干制剂的制备方法
CN116920114A (zh) 稳定的干扰素融合蛋白制剂及其应用
WO2024261766A1 (en) Lyophilised vaccine formulation

Legal Events

Date Code Title Description
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000